来源:药渡撰文:Pharmadeep编辑:活力哈哈在近日于旧金山举办的第44届摩根大通医疗健康大会上,德琪医药(股票代码:6996.HK)以其扎实的临床数据与前瞻性的技术布局,再次向全球生物医药界展示了其深厚的研发实力与清晰的战略方向。公司不仅公布了核心管线ATG-022的最新临床数据,更系统性地展示了其在下一代抗体偶联药物及自主研发的T细胞衔接器平台领域的全面布局,描绘出一幅在肿瘤与自身免疫...
Source Link来源:药渡撰文:Pharmadeep编辑:活力哈哈在近日于旧金山举办的第44届摩根大通医疗健康大会上,德琪医药(股票代码:6996.HK)以其扎实的临床数据与前瞻性的技术布局,再次向全球生物医药界展示了其深厚的研发实力与清晰的战略方向。公司不仅公布了核心管线ATG-022的最新临床数据,更系统性地展示了其在下一代抗体偶联药物及自主研发的T细胞衔接器平台领域的全面布局,描绘出一幅在肿瘤与自身免疫...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.